《蓝筹》京东健康(06618.HK)首季非国际财务报告准则盈利按年升47.7%

阿斯达克财经
13 May

京东健康(06618.HK) 公布截至今年3月底止首季业绩,非国际财务报告准则经营盈利13.08亿元(下同),按年升73.4%。非国际财务报告准则盈利17.68亿元,按年升47.7%。收入166.45亿元人民币,按年升25.5%。

集团指,期内首发多款创新药品,包括辉瑞旗下泰泽纳(甲苯磺酸他拉唑帕利胶囊)、Esteve旗下的利舒仁(米托坦片)、银诺医药旗下怡诺轻,以及健民集团旗下龙牡小儿紫贝宣肺糖浆等。(ss/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-13 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10